TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04640532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895, administered by mouth
Study: NCT02398461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHIgM22
Description: Administered via IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04640532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895, administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895, administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895, administered by mouth
Study: NCT01489995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A (migalastat)
Description: 150 mg migalastat HCl in the fasting state (reference arm)
Study: NCT01895920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Study: NCT01489995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B (migalastat)
Description: 150 mg migalastat HCl with simultaneous consumption of a glucose drink

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C (migalastat)
Description: 150 mg migalastat HCl 1 hour before consumption of a high fat meal
Study: NCT00424814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra (lopinavir/ritonavir)
Description: (200/50 mg x2)x 2/d= 2 pills twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)
Description: Kaletra (lopinavir/ritonavir): (200/50 mg x2)x 2/d= 2 pills twice daily Combivir (zidovudine/lamivudine): (300/150mg) x 2/d=1 pill twice daily
Study: NCT01200056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg versus 40mg.
Description: 2 arms comparing atorvastatin 10mg daily for 6 months to atorvastatin 40mg daily for 6 months. The primary endpoint would be the 6 months VH-IVUS findings and clinical outcomes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg versus 40mg.
Description: 2 arms comparing atorvastatin 10mg daily for 6 months to atorvastatin 40mg daily for 6 months. The primary endpoint would be the 6 months VH-IVUS findings and clinical outcomes.
Study: NCT02131896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventional arm-Mediterranean diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm- regular nutritional instructions in accordance with the accepted nutritional guidelines
Study: NCT03567057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADS-5102, 274 mg
Description: Oral capsules
Study: NCT01961791

Intervention type: PROCEDURE
Intervention: gastrectomy
Description: gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer

Intervention type: PROCEDURE
Intervention: gastrectomy
Description: gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
Study: NCT03339882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifemin
Description: Remifemin 0.2g po bid\*12 weeks at the beginning of the LHRH-a treatment
Study: NCT05998213

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fecal microbiota transplant
Description: Frozen FMT via duodenal tube (2 times) and enemas (4 times)
Study: NCT01489995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D (migalastat)
Description: 150 mg migalastat HCl 1 hour before consumption of a light meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E (migalastat)
Description: 150 mg migalastat HCl 1 hour after consumption of a light meal
Study: NCT02557152

Intervention type: DEVICE
Intervention: GentleWave System Treatment
Study: NCT03178266

Intervention type: DEVICE
Intervention: Knee Arthroplasty
Description: Standard Knee Arthroplasty will be performed on study subjects. The closure method will be studied at 3 weeks and 6 weeks and patients will be asked about satisfaction with the closure method assigned.

Intervention type: DEVICE
Intervention: Knee Arthroplasty
Description: Standard Knee Arthroplasty will be performed on study subjects. The closure method will be studied at 3 weeks and 6 weeks and patients will be asked about satisfaction with the closure method assigned.
Study: NCT03756428

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep dry needling in tibialis posterior
Description: The inspector, with gloves, disinfects the area to be treated with 70º alcohol. Once the alcohol is applied, the intervenor locates and takes the myofascial trigger point and places the needle with the guide tube resting on the skin of the patient. The inspector holds the guide tube between the index and middle fingers lightly touch the needle with the index finger of the other hand to insert the needle perpendicularly into the skin, directing it towards the inspector's thumb. Once the needle is inserted subcutaneously, the guide tube is removed. The controller deepens the needle to myofascial trigger point, and makes fast inputs and outputs into it. The rapid exit is made to the subcutaneous cellular tissue, outside the muscle, but not outside the skin. Next, hemostasis is performed in the area. Once this hemostasis is completed, the patient is incorporated and dressed.
Study: NCT03756428

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham technique in tibialis posterior
Description: The patient lies on the stretcher without the trousers. The interventor, with the guide tube, simulates the technique of puncture in the right twin of the subject. The comptroller cleans the area with 70º alcohol. Once the alcohol is applied, he performs the simulated dry needling technique in a plane with his index and middle fingers with the guide tube. It is important that the subject has his head stuck in the hollow of the head of the stretcher throughout the technique to make a correct masking.
Study: NCT05998213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant
Description: Frozen FMT via duodenal tube (2 times) and enemas (4 times)
Study: NCT04345978

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fasting hours
Description: Normal Fasting hours before CRC surgery for 8 hours and feeding 8 hours after surgery; Prolong fasting hours before CRC surgery for 24 hours and feeding 24 hours after surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting hours
Description: Normal Fasting hours before CRC surgery for 8 hours and feeding 8 hours after surgery; Prolong fasting hours before CRC surgery for 24 hours and feeding 24 hours after surgery.
Study: NCT01641744

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Systematic Training for Effective Parenting (STEP)
Description: Parenting skills training class, 1x/week, 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Attachment Based Intervention (GABI)
Description: Parent-child group, 3x/week, 26 weeks
Study: NCT01056757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000 mg bid, po, q28days
Study: NCT03222648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Responsive Exercise Training
Description: Twice weekly, 8 week structured responsive exercise training programme. Protocol used the same as that used in previous EMPOWER Trial (Loughney et al. 2016)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Continuation of usual care
Study: NCT00338065

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postural change
Description: Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postural change
Description: Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postural change
Description: Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postural change
Description: Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Water drinking
Description: Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water drinking
Description: Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water drinking
Description: Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water drinking
Description: Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking.
Study: NCT00421551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: during the 48 first weeks of the trial, (2x300mg) twice a day between W48 and W96, (2x400mg) once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: during the 48 first weeks of the trial, (2x300mg) twice a day between W48 and W96, (2x400mg) once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: during the first 48 weeks, 100mg twice a day between W48 and W96, 100mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: during the first 48 weeks, 100mg twice a day between W48 and W96, 100mg once a day
Study: NCT00223834

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: single session of Motivational Interviewing
Study: NCT00220298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) - NebidoTM
Description: Drug treatment with 14 injections of one ampoule of Nebido (1000 mg of testosterone undecanoate) at individually adjusted injection intervals
Study: NCT03963908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AtEase
Description: AtEase is a tailored pain self-management mobile app that tailors participant's feedback based on readiness to engage in pain self-management and preference for self-management strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Pain Education
Description: CBT-based Education on Pain Self-Management for Veterans
Study: NCT04879914

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Butyrate
Description: 3 cps/die 300 mg/cps

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 cps/die 300 mg/cps
Study: NCT02774070

Intervention type: RADIATION
Group type: OTHER
Intervention: Plain X-ray
Description: antero-posterior, lateral neutral, flexion, extension and open-mouth views

Intervention type: RADIATION
Group type: OTHER
Intervention: Plain X-ray
Description: antero-posterior, lateral neutral, flexion, extension and open-mouth views

Intervention type: RADIATION
Group type: OTHER
Intervention: Magnetic resonance imaging
Description: Magnetic resonance imaging sagittal T1W,T2W and STIR, axial T1W and coronal T2W and post contrast sagittal and axial sequences

Intervention type: RADIATION
Group type: OTHER
Intervention: Magnetic resonance imaging
Description: Magnetic resonance imaging sagittal T1W,T2W and STIR, axial T1W and coronal T2W and post contrast sagittal and axial sequences
Study: NCT04355351

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: blood sampling done on hospital staff without sars-coV-2 symptoms

Intervention type: OTHER
Group type: OTHER
Intervention: additional blood tubes
Description: Additionnal blood tube taken during the classical blood sampling in hospital
Study: NCT04483960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Arm Closed) Nafamostat Mesilate
Description: Nafamostat continuous IV infusion for 7 days or until day of hospital discharge at a dose of 0.2mg/kg/hour. No adjustment in dose is needed for renal impairment, including for renal dialysis. The daily dose of nafamostat should be administered in 500 mL (rate of infusion 20.8 mL/hour) of normal saline. Normal saline is recommended (due to the tendency for patients with COVID-19 towards hyponatraemia) but not mandated, and 5% dextrose would be acceptable if felt clinically appropriate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Arm Closed) Enoxaparin
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Enoxaparin will be 1mg/kg q12h or 1.5mg/kg q24h.
Study: NCT03749564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMT
Description: The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort.
Study: NCT04483960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Arm Closed) Enoxaparin
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Enoxaparin will be 1mg/kg q12h or 1.5mg/kg q24h.
Study: NCT03837912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient reported safety experiences fed back to PC providers
Description: The intervention will involve three key stages: a) Measurement: Patients will be invited to complete the Patient Reported Experiences and Outcomes of Safety in Primary Care (PREOS-PC) questionnaire using a tablet-computer. b) Feedback: Using a bespoke online tool, the information will be processed and presented to each centre in the form of a Feedback Report, which will offer comparisons with other centres along with a set of recommendations for addressing the problems identified. c) Action planning and change: centres will form an Action Planning Team, which will be responsible for analyzing the report, considering which area(s) should be improved, and developing, implementing and monitoring an action plan to address the safety problems identified.
Study: NCT02251990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir
Description: FDC tablet containing 100 mg of grazoprevir and 50 mg of elbasvir taken q.d. by mouth for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching grazoprevir/elbasvir FDC tablet taken q.d. by mouth for 12 weeks.
Study: NCT03626597

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urine Pregnancy Test
Description: CHV will provide all participants with in-person urine pregnancy tests (UPTs)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urine Pregnancy Test
Description: CHV will provide all participants with in-person urine pregnancy tests (UPTs)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHV-based post-test counseling & referral
Description: CHVs will provide in-person post-test counseling \& referral to care
Study: NCT04483960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Arm Closed) Enoxaparin
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Enoxaparin will be 1mg/kg q12h or 1.5mg/kg q24h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Arm Closed) Dalteparin
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Dalteparin will be 100IU/kg q12h or 200IU/kg q24h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Arm Closed) Dalteparin
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Dalteparin will be 100IU/kg q12h or 200IU/kg q24h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Arm Closed) Dalteparin
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Dalteparin will be 100IU/kg q12h or 200IU/kg q24h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Arm Closed) Tinzaparin
Description: Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Tinzaparin will be 175IU/kg q24h (not available within Australia).
Study: NCT03626597

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone-based post-test counseling & referral
Description: Participants will call/SMS or be called/SMSed for phone-based counseling \& referral to care
Study: NCT01792180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobility feedback device with use of instruction book
Description: Weekly use of the mobility feedback device to measure gait speed. Two infrared sensors will be placed in the line of walking, a photo frame containing a display, symbols and lights will tell the participant when and how to perform the test. Gait speed is shown on the display and will serve as feedback to the participant. Participant can use their gait speed to decide which exercises from the instruction book he performs. Participants will be asked to keep an activity diary.
Study: NCT04872764

Intervention type: OTHER
Intervention: duration of hospitalization, mortality rate
Description: duration of hospitalization, mortality rates of patients hospitalised for COVID-19 evaluated and compared in patients with and without acute kidney injury.

Intervention type: OTHER
Intervention: duration of hospitalization, mortality rate
Description: duration of hospitalization, mortality rates of patients hospitalised for COVID-19 evaluated and compared in patients with and without acute kidney injury.
Study: NCT03071055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Injection [Lucentis]
Description: intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab Injection [Lucentis]
Description: intravitreal injection
Study: NCT01342874

Intervention type: DIETARY_SUPPLEMENT
Intervention: Inositol
Description: inositol exposure in early GDM
Study: NCT04204629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1601 40mg
Description: Single dosing of HIP1601 40mg, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1601 40mg
Description: Single dosing of HIP1601 40mg, PO
Study: NCT01187693

Intervention type: OTHER
Group type: OTHER
Intervention: shoe lift
Description: shoe lift for balancing the heights of bilateral pelvis of participants with leg length discrepancy during standing
Study: NCT03608930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable Polypectomy Snare,JHY-SD-23-230-30-A1
Description: The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation.
Study: NCT02303184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg CLS-TA
Description: 40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: suprachoroidal sham procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVT aflibercept
Description: 2 mg intravitreal injection of aflibercept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVT aflibercept
Description: 2 mg intravitreal injection of aflibercept
Study: NCT03401684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilient Minds
Description: The program is designed: 1) to decrease the risk of developing a stress disorder or other mental illnesses due to workplace incidents and/or unhealthy stress; 2) to mitigate the negative impacts of mental illness and trauma through early recognition and early intervention; 3) to support the public while on the frontline; and 4) to improve the psychological health of fire staff while cultivating resilience and enhancing quality of life.